Page last updated: 2024-11-04

amrinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amrinone is a synthetic, non-glycosidic, inotropic agent with vasodilator activity. It is a phosphodiesterase inhibitor that increases intracellular cyclic adenosine monophosphate (cAMP) levels. This leads to increased contractility and relaxation of smooth muscle, resulting in positive inotropic effects and vasodilation. Amrinone was initially studied for its potential to improve cardiac function in patients with heart failure. However, its use is limited due to adverse effects such as arrhythmias, gastrointestinal disturbances, and hepatotoxicity. It is still occasionally used in patients with severe heart failure who are refractory to other therapies.'

Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID3698
CHEMBL ID12856
CHEBI ID2686
SCHEMBL ID44012
SCHEMBL ID13457017
MeSH IDM0001038

Synonyms (149)

Synonym
AC-12186
MLS001074083
AB00052312-04
BRD-K45924332-001-04-4
KBIO1_000136
DIVK1C_000136
cartonic
amcoral
wincoram
inocor
win-40680
MLS000069829 ,
smr000058850
5-amino-3,4'-bipyridin-6(1h)-one
ccris 3794
brn 0744819
amrinonum [inn-latin]
3-amino-5-(4-pyridinyl)-2(1h)-pyridinone
awd 08-250
cordemcura
win 40680
5-amino-(3,4'-bipyridin)-6(1h)-one
(3,4'-bipyridin)-6(1h)-one, 5-amino-
amrinona [inn-spanish]
einecs 262-390-0
5-amino(3,4'-bipyridin)-6(1h)-one
SPECTRUM_001350
PRESTWICK3_000800
amrinone
60719-84-8
PRESTWICK_44
cas-60719-84-8
NCGC00016896-01
BPBIO1_001034
PRESTWICK2_000800
IDI1_000136
BSPBIO_000940
SPECTRUM5_000999
inamrinone
DB01427
inamrinone (usp)
D00231
amcoral (tn)
amrinone (jan/inn)
NCGC00095984-01
NCGC00164379-01
KBIO3_002052
KBIOGR_001398
KBIOSS_001830
KBIO2_001830
KBIO2_006966
KBIO2_004398
SPECTRUM4_001069
PRESTWICK1_000800
SPECTRUM3_000956
SPBIO_002139
PRESTWICK0_000800
NINDS_000136
SPBIO_002879
SPECTRUM2_001980
SPECTRUM1503084
CHEMBL12856 ,
nsc-759805
vesistol
c01ce01
HMS500G18
HMS1570O22
3-amino-5-pyridin-4-yl-1h-pyridin-2-one
3-azanyl-5-pyridin-4-yl-1h-pyridin-2-one
A832852
HMS2097O22
HMS3264E16
tox21_301847
dtxsid9022603 ,
dtxcid602603
NCGC00255137-01
tox21_112110
pharmakon1600-01503084
nsc759805
5-amino-[3,4'-bipyridin]-6(1h)-one
STK590307
HMS2234F12
CCG-39487
NCGC00016896-03
NCGC00016896-02
AKOS005512516
unii-jut23379tn
amrinone [inn]
amrinona
inamrinone [usan:usp]
jut23379tn ,
amrinonum
nsc 759805
5-25-15-00181 (beilstein handbook reference)
FT-0601595
5-amino-3,4'-bipyridyl-6(1h)-one
inamrinone [usp monograph]
inamrinone [vandf]
inamrinone [usan]
amrinone [mi]
amrinone [who-dd]
amrinone [jan]
amrinone [usp-rs]
inamrinone [usp impurity]
amrinone [mart.]
amrinone [vandf]
gtpl7202
3-amino-5-(pyridin-4-yl)pyridin-2-ol
HMS3369J10
SCHEMBL44012
NCGC00016896-06
tox21_112110_1
KS-5178
SCHEMBL13457017
bdbm34651
cid_3698
3-amino-5-(4-pyridinyl)-2(1h)pyridinone
5-amino-(3,4?-bipyridin)-6(1h)-one
W-105234
AC-33137
[3,4'-bipyridin]-6(1h)-one, 5-amino-
5-amino(3,4'-bipyridine)-6-(1h)-one
3-amino-5-(4-pyridinyl)-1,2-dihydro-2-pyridone
5-amino[3,4'-bipyridin]-6(1h)-one
AB00052312_05
OPERA_ID_1054
3-amino-5-(pyridin-4-yl)-1,2-dihydropyridin-2-one
SR-00000002445-2
sr-00000002445
amrinone, united states pharmacopeia (usp) reference standard
216151-27-8
CHEBI:2686
HMS3714O22
3-amino-5-(pyridin-4-yl)pyridin-2(1h)-one
Q422724
amrinone,(s)
HY-B1294
BCP12764
BRD-K45924332-001-07-7
CS-0013064
C75837
cid 5281003
3-amino-5-pyridin-4-ylpyridin-2-ol
NCGC00016896-04
EN300-6477374
BA166404
5-amino-[3,4 inverted exclamation mark -bipyridin]-6(1h)-one
SY112917
Z1198150288

Research Excerpts

Overview

Arinone is a bipyridine compound with characteristic effects on the force-velocity relationship of fast skeletal muscle. It has been widely used for treatment of left heart failure. Amrinone was found to be a direct pulmonary vasodilator with a threshold dose of 0.3 mg/kg.

ExcerptReferenceRelevance
"Amrinone is a bipyridine compound with characteristic effects on the force-velocity relationship of fast skeletal muscle, including a reduction in the maximum shortening velocity and increased maximum isometric force. "( Drug effect unveils inter-head cooperativity and strain-dependent ADP release in fast skeletal actomyosin.
Albet-Torres, N; Barman, T; Bloemink, MJ; Candau, R; Frölander, K; Geeves, MA; Golker, K; Herrmann, C; Lionne, C; Månsson, A; Piperio, C; Schmitz, S; Veigel, C, 2009
)
1.8
"Amrinone is a new noncatechol, nonglycoside agent with cardiotonic and vasodilator properties. "( The effects of amrinone on transport and cyclic AMP metabolism in toad urinary bladder.
Jacoby, M; Levine, SD; Satriano, JA; Schlondorff, D, 1981
)
2.06
"Amrinone is a bipyridine derivative with positive inotropic effects and vasodilatory properties. "( Amrinone. A preliminary review of its pharmacological properties and therapeutic use.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM; Ward, A, 1983
)
3.15
"Amrinone is an effective inotropic agent, but its electrophysiologic effects in humans have not been previously determined. "( Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure.
Dougherty, AH; Goldstein, RA; Gray, EL; Hanna, JE; Naccarelli, GV, 1984
)
3.15
"Amrinone is a positive inotropic agent which has been widely used for treatment of left heart failure. "( [Right ventricular hemodynamics and lung function following amrinone injection].
Baur, X; Fruhmann, G; Hauser, F; Klepzig, M; Mernitz, G; Strauer, BE, 1984
)
1.95
"Amrinone was found to be a direct pulmonary vasodilator with a threshold dose of 0.3 mg/kg."( Pulmonary vascular effects of amrinone in conscious lambs.
Einzig, S; Kulik, TJ; Lock, JE; Mammel, MC; Thompson, TR, 1983
)
1.28
"Amrinone is a cardiotonic agent associated with reversible thrombocytopenia in 20% to 50% of patients. "( Effect of oral amrinone on platelet function and survival.
Brandt, JT; Hermiller, J; Leier, CV; Miller, L; Unverferth, DV, 1984
)
2.06
"Amrinone is a rapidly acting vasodilator which blunts vasoconstriction due to hypoxia or angiotensin II."( Amrinone dilates pulmonary vessels and blunts hypoxic vasoconstriction in isolated rat lungs.
Hill, NS; Rounds, S, 1983
)
2.43
"Amrinone is a promising, orally effective inotropic agent for patients with refractory congestive cardiac failure, but is limited to its tendency to cause thrombocytopaenia."( Amrinone--a new inotropic agent in chronic resistant congestive cardiac failure.
Barrett, PA; Chong, B; Lvoff, R; Robinson, PJ, 1981
)
2.43
"Amrinone appears to be a promising agent for the long-term treatment of chronic cardiac failure; the utility of pirbuterol, an oral catecholamine analog, remains to be determined."( Cardiotonic agents in the management of chronic cardiac failure.
Andrews, V; Janicki, JS; Weber, KT, 1982
)
0.99
"Amrinone is a new synthetic drug that increases contractile strength of mammalian heart muscle; however, its mechanism of positive inotropic action has not been determined. "( Amrinone activates K+-depolarized atrial and ventricular myocardium of guinea pigs.
Adams, HR; Rhody, J; Sutko, JL, 1982
)
3.15
"Amrinone is a non-glycoside positive inotropic agent with an inhibitory effect on a cyclic adenosine monophosphate (AMP) phosphodiesterase isoenzyme. "( Beneficial effect of amrinone on murine cardiac allograft survival.
Furukawa, Y; Hirozane, T; Matoba, Y; Matsui, S; Matsumori, A; Sasayama, S; Sato, Y, 1995
)
2.05
"Amrinone is a noncatecholamine inotropic agent used clinically in the management of heart failure. "( Amrinone improves survival in hemorrhagic shock.
Cinat, M; Daughters, K; Waxman, K, 1994
)
3.17
"Amrinone is an effective agent by itself, but is especially useful in combination with a beta-adrenergic agonist for patients with severe left-ventricular dysfunction."( Selecting an inotrope for the cardiac surgery patient.
Butterworth, J, 1993
)
1.01
"Amrinone by itself is an effective agent to facilitate weaning from CPB, and therapy with amrinone reduced the need for individualized titration of epinephrine. "( Amrinone in cardiac surgical patients with left-ventricular dysfunction. A prospective, randomized placebo-controlled trial.
Butterworth, JF; Lawless, ST; Prielipp, RC; Royster, RL; Wallenhaupt, SL, 1993
)
3.17
"Amrinone is a bipyridine derivative with inotropic and vasodilator effects that have not been systematically evaluated in the pediatric patient with increased pulmonary blood flow."( Selective pulmonary and systemic vasodilator effects of amrinone in children: new therapeutic implications.
Gelband, H; Mas, MS; Robinson, BW, 1993
)
1.97
"Amrinone is an inotropic agent that does not critically augment myocardial oxygen demand and may be useful for identification of hibernating myocardium in the chronically ischemic state."( Amrinone stimulation test: ability to predict improvement in left ventricular ejection fraction after coronary bypass surgery in patients with poor baseline left ventricular function.
Boullon, F; Brown, KA; Cragnolino, DE; Masoli, OH; Mele, E; Meretta, AH; Palacios, I; Perez-Baliño, NA; Perrone, S; Rodriguez, A, 1996
)
2.46
"Amrinone is a clinically used positive inotropic agent which elevates intracellular cAMP and cGMP levels by selective inhibition of the phosphodiesterase III isoenzyme."( Effect of the phosphodiesterase III inhibitor amrinone on cytokine and nitric oxide production in immunostimulated J774.1 macrophages.
Haskó, G; Németh, ZH; Salzman, AL; Szabó, C; Vizi, ES, 1997
)
1.28
"Amrinone is a selective phosphodiesterase III inhibitor that increases cyclic adenosine monophosphate by preventing its breakdown. "( Clinical use of amrinone (a selective phosphodiesterase III inhibitor) in reconstructive surgery.
Harii, K; Ichioka, S; Nakatsuka, T; Ohura, N; Sato, Y, 2001
)
2.1
"Amrinone is an effective inotrope useful in the cardiovascular support of hyperdynamic patients following surgical stress."( Amrinone as an inotrope in managing hypermetabolic surgical stress.
Donovan, R; Scalea, TM, 1992
)
2.45
"Amrinone is a nonglycosidic noncatecholamine with both vasodilator and positive inotropic effects that may be administered to patients undergoing cardiac surgery. "( Pharmacokinetics of amrinone during cardiac surgery.
Bailey, JM; Hug, CC; Levy, JH; Rogers, HG; Szlam, F, 1991
)
2.05
"Amrinone was found to be a powerful peripheral vasodilator with a mild positive inotropic action."( Quantitative assessment of the effects of 'inodilators' on the myocardium in patients without primary cardiac insufficiency after coronary surgery: Part I--Amrinone.
Engel, C; Flameng, W; Geiger, A; Isringhaus, H; Lunkenheimer, PP; Peterschmidt, O; Redmann, K; Rettig, G, 1991
)
1.2
"Amrinone is a potent alternative which combines positive inotropic and vasodilating properties."( [The treatment of heart insufficiency in coronary heart disease].
Bertel, O; Gerber, A, 1991
)
1
"Amrinone is a positive inotropic and vasodilatory agent and may be administered during anesthesia with isoflurane. "( Amrinone reverses cardiac depression and augments coronary vasodilation with isoflurane in the isolated heart.
Bosnjak, ZJ; Kampine, JP; Marijic, J; Rooney, RT; Stowe, DF, 1991
)
3.17
"Amrinone is a selective inhibitor of phosphodiesterase fraction 3 in both cardiac and smooth muscle. "( Amrinone: pharmacokinetics and pharmacodynamics.
Bailey, JM; Levy, JH, 1989
)
3.16
"Amrinone is a bipyridine derivative with positive inotropic and vasodilator properties. "( Effects of amrinone and dopamine on uterine blood flow and vascular responses in the gravid baboon.
Ashrafzadeh, AR; Dormer, KJ; Fishburne, JI; Gill, PS; Payne, GG; Rossavik, IK, 1988
)
2.11
"Amrinone is a nonadrenergic, nonglycosidic agent with combined positive inotropic and vasodilator properties. "( [Use of amrinone in refractory cardiac insufficiency: clinical and hemodynamic evaluation].
Bertoni, T; De Martini, M; Foresti, A; Lotto, A; Massari, FM; Valentini, R, 1986
)
2.15
"Amrinone is an effective vasodilator without altering systolic and mean arterial blood pressure or heart rate strongly."( [Peripheral hemodynamics and metabolic parameters influenced by amrinone at rest and following handgrip stress].
Griebenow, R; Peters, P; Saborowski, F, 1986
)
1.23
"Amrinone is a new positive inotropic agent available in oral and intravenous preparations. "( [Effects of amrinone administered orally and by injection in heart failure].
Bounhoure, JP; Calazel, J; Massabuau, P; Miquel, JP; Puel, J, 1985
)
2.09

Effects

Aminrinone has a narrow therapeutic-toxic ratio, but a significant proportion (42%) of patients tolerate and benefit from amrinone therapy.

Arinone has been reported to accelerate the cooling rate but not the rewarming rate of core temperature during deliberate mild hypothermia. The drug has protections against lung I/R injury, possibly through its anti-oxidation effects.

ExcerptReferenceRelevance
"Amrinone has a superior profile of myocardial efficiency on the postischemic myocardium since it does not produce the oxygen-wasting effe"( The effects of amrinone versus dobutamine on myocardial mechanics and energetics after hypothermic global ischemia.
Berman, K; Fahey, AL; Isom, OW; Ko, W; Krieger, KH; Lang, D; Zelano, JA, 1993
)
1.36
"Amrinone has a narrow therapeutic-toxic ratio, but a significant proportion (42%) of patients tolerate and benefit from amrinone therapy."( Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure.
Gerber, L; Merrill, AJ; Silverman, BD, 1985
)
1.26
"Amrinone has been reported to accelerate the cooling rate but not the rewarming rate of core temperature during deliberate mild hypothermia."( High-dose amrinone is required to accelerate rewarming from deliberate mild intraoperative hypothermia for neurosurgical procedures.
Furuya, H; Inoue, S; Kawaguchi, M; Kitaguchi, K; Sakaki, T; Sakamoto, T, 2002
)
1.44
"Amrinone has protections against lung I/R injury, possibly through its anti-oxidation effects and an inhibition of inflammation factors releasing."( [Protection of amrinone against lung injury induced by ischemia/reperfusion in rats].
Gong, SG; Liu, JM, 2007
)
2.14
"Amrinone has been compared with dopamine, dobutamine, pirbuterol and prazosin in preliminary short terms studies in patients with severe congestive heart failure, although more studies are needed before any relative clinical advantages or disadvantages can be ascribed to amrinone."( Amrinone. A preliminary review of its pharmacological properties and therapeutic use.
Avery, GS; Brogden, RN; Heel, RC; Speight, TM; Ward, A, 1983
)
2.43
"Amrinone has been shown to produce haemodynamic benefits in digitalis-treated patients. "( Non-additive positive inotropic effects of amrinone and ouabain on cat papillary muscles.
Brown, L; Erdmann, E, 1984
)
1.97
"Amrinone has been shown to exhibit a potent inotropic effect in patients with heart failure secondary to congestive cardiomyopathy, but its effects on myocardial oxygen consumption (MVO2) and coronary blood flow (CBF) are unknown. "( Effects of amrinone on myocardial energy metabolism and hemodynamics in patients with severe congestive heart failure due to coronary artery disease.
Benotti, JR; Braunwald, E; Carabello, BA; Grossman, W, 1980
)
2.09
"Amrinone has been increasingly used in management of low cardiac output syndrome during anesthesia, particularly when associated with right heart failure and pulmonary hypertension. "( Comparative vasoactive effects of amrinone on systemic and pulmonary arteries in rabbits.
Hou, X; Lee, TS, 1995
)
2.01
"Amrinone has potent venous and arterial vasodilating properties that make it a unique drug for treating congestive heart failure in addition to its reported positive inotropic effects."( Amrinone: its effect on vascular resistance and capacitance in human subjects.
Bailey, JM; Levy, JH, 1994
)
2.45
"Amrinone has a superior profile of myocardial efficiency on the postischemic myocardium since it does not produce the oxygen-wasting effe"( The effects of amrinone versus dobutamine on myocardial mechanics and energetics after hypothermic global ischemia.
Berman, K; Fahey, AL; Isom, OW; Ko, W; Krieger, KH; Lang, D; Zelano, JA, 1993
)
1.36
"Amrinone and glucagon have been used separately and in combination with other agents in the treatment of calcium channel blocker overdose."( Use of amrinone and glucagon in a case of calcium channel blocker overdose.
Otten, EJ; Spadafora, MP; Wolf, LR, 1993
)
1.46
"Amrinone has been shown to have therapeutic effects on bupivacaine-induced cardiovascular toxicity, but its exact effects on the heart are not well understood. "( Amrinone reverses bupivacaine-induced regional myocardial dysfunction.
Fujita, Y, 1996
)
3.18
"Amrinone has potent inodilator effects because of its dual mechanism of action."( [Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation].
Hagihira, S; Inagaki, Y; Mashimo, T; Mori, T; Okuno, Y; Takashina, M; Yoshiya, I, 1997
)
1.33
"Amrinone has not only vasodilative effects, but definite positive inotropic effects in infants with heart failure."( Cardiovascular effects of a phosphodiesterase III inhibitor, amrinone, in infants: non-invasive echocardiographic evaluation.
Motomura, H; Nakazawa, M; Takeda, A; Teshima, H; Tobita, K; Yamamura, H, 2002
)
2
"Amrinone has been utilized in medical patients with heart failure, but its use in hyperdynamic patients to our knowledge has never been reported."( Amrinone as an inotrope in managing hypermetabolic surgical stress.
Donovan, R; Scalea, TM, 1992
)
2.45
"Amrinone has been shown to have a beneficial effect on left ventricular function in low output syndrome (LOS), but its use after open-heart surgery has not been extensively revised. "( Amrinone in perioperative low cardiac output syndrome.
Fita, G; Gomar, C; Jimenez, MJ; Mulet, J; Nalda, MA; Pacheco, M, 1990
)
3.16
"Amrinone (A) has been administered to 10 patients with low postoperative cardiac output as unique inotropic therapy and to 34 patients in severe cardiogenic shock, despite optimal treatment."( New inotropic-vasodilating drugs in acute and chronic heart failure.
Goenen, MJ, 1986
)
0.99
"Amrinone has a narrow therapeutic-toxic ratio, but a significant proportion (42%) of patients tolerate and benefit from amrinone therapy."( Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure.
Gerber, L; Merrill, AJ; Silverman, BD, 1985
)
1.26

Actions

Aminoquin was found to increase phasic tension of ferret papillary muscles only for depolarizations lasting less than 250 to 300 msec. Amrinone produced an increase in CO comparable to that of OPC-18790; however, the increase in peak LVdP/dt was smaller.

ExcerptReferenceRelevance
"Amrinone did not produce oscillatory afterpotentials, influence ouabain-induced afterpotentials, or alter overdrive-induced depolarization."( In vitro electrophysiologic properties of amrinone in mammalian cardiac tissue.
Canniff, PC; Farah, AE; Piwonka, RW,
)
1.12
"Amrinone appears to increase the metabolic vasodilatation by potentiating the vasodilator action of adenosine."( Responses of isolated dog arteries to amrinone.
Miyazaki, M; Nakajima, M; Nishimura, K; Toda, N, 1984
)
1.26
"Amrinone produced an increase in CO comparable to that of OPC-18790; however, the increase in peak LVdP/dt was smaller while the increase in HR and decrease in mBP were larger than those seen with OPC-18790."( Effects of OPC-18790, a new positive inotropic agent, on energetics in the ischaemic canine heart: a 31P-MRS study.
Fujiki, H; Ishikawa, M; Itoh, S; Koga, K; Mori, T; Tominaga, M; Yabuuchi, Y, 1995
)
1.01
"Amrinone led to a 23% increase in cardiac index resulting mainly from reduction in afterload."( Effects of amrinone on left and right ventricular function in patients with impaired myocardial performance during general anaesthesia.
Dütschke, P; Petry, A, 1994
)
1.4
"Amrinone did not produce significant increases in preload recruitable stroke work area at 0.75 mg/kg; amrinone's inotropic effect was equivalent to dobutamine, 5 micrograms/kg per minute at 1.5 mg/kg, and at the maximum dose (3.0 mg/kg) it was equivalent to dobutamine, 10 micrograms/kg per minute."( The effects of amrinone versus dobutamine on myocardial mechanics and energetics after hypothermic global ischemia.
Berman, K; Fahey, AL; Isom, OW; Ko, W; Krieger, KH; Lang, D; Zelano, JA, 1993
)
1.36
"Amrinone induced a 27% increase in ejection fraction at 10 min (from 44% to 56%) as a result of both a significant rise in contractility (mean Ees 4 +/- 2 to 6 +/- 3 mm Hg/ml, p less than 0.001) and simultaneous reduction in arterial loading (Ea reduction from 6 +/- 2 mm Hg/ml to 5 mm Hg/ml, p less than 0.001)."( Pressure-volume analysis as a method for quantifying simultaneous drug (amrinone) effects on arterial load and contractile state in vivo.
Grayson, R; Kass, DA; Marino, P, 1990
)
1.23
"When amrinone is used, the increase in myocardial oxygen consumption due to increased contractility is offset by the reductions in preload and afterload."( [Amrinone (Wincoram)--a new positive inotropic and vasodilator agent].
Hess, W, 1988
)
1.64
"Amrinone was found to inhibit platelet aggregation in human whole blood in a dose dependent manner, and at physiological levels of the drug. "( The in vitro effect of amrinone on platelet aggregation in human whole blood.
Bonner, FW; Eason, CT; Pattison, A, 1986
)
2.02
"Thus amrinone appears to cause relaxation of intestinal smooth muscle from different species by hindering the stimulatory effect of endogenous adenosine."( Possible role of adenosine in the relaxant effect of amrinone on guinea-pig ileum.
Ceroni, G; Dorigo, P; Gaion, RM; Giacometti, A; Maragno, I, 1987
)
0.98
"Amrinone did not increase plasma catecholamine levels with either anesthetic."( Amrinone blunts cardiac depression caused by enflurane or isoflurane anesthesia in the dog.
Kapur, PA; Makela, VH, 1987
)
2.44
"Amrinone was found to increase phasic tension of ferret papillary muscles only for depolarizations lasting less than 250 to 300 msec."( Amrinone effects on electromechanical coupling and depolarization-induced automaticity in ventricular muscle of guinea pigs and ferrets.
Arlock, P; Katzung, BG; Malécot, CO, 1985
)
2.43

Treatment

Aminor systemic vasodilation and stroke volume increase at a lower diltiazem dose. Amrinone-treated dogs had lower PaO2 and higher venous admixture than the control dogs. Treatment with amrinone potentiated the relaxant responses of mesenteric arteries to adenosine.

ExcerptReferenceRelevance
"Oral amrinone treatment, at 40 mg/kg per day, significantly prolonged median cardiac allograft survival compared with non-treated controls (22.0 days versus 10.5 days, P < 0.01) when DBA/2 mouse hearts (H-2d) were heterotopically transplanted into C57B1/6 mice (H-2b)."( Beneficial effect of amrinone on murine cardiac allograft survival.
Furukawa, Y; Hirozane, T; Matoba, Y; Matsui, S; Matsumori, A; Sasayama, S; Sato, Y, 1995
)
1.07
"In amrinone-treated patients, cardiac index (CI) increased significantly by 48 +/- 14% following CPB (T3) versus 10 +/- 10% for placebo-treated patients (P = 0.029)."( An amrinone bolus prior to weaning from cardiopulmonary bypass improves cardiac function in mitral valve surgery patients.
Badner, NH; Murkin, JM; Shannon, NA, 1994
)
1.42
"In amrinone treated patients bolus dose of amrinone 1.5 mg.kg-1 was administrated into the reservoir of CPB and followed by continuous infusion at a rate of 5 micrograms.kg-1.min-1."( [Effects of amrinone on oxygen demand-supply relationship after cardiopulmonary bypass in patient undergoing coronary bypass surgery].
Furuya, H; Kaneko, M; Kawaguchi, M; Kitaguchi, K; Nishimura, K; Sakamoto, T; Sha, K; Shimokawa, M, 1997
)
1.19
"Amrinone pretreatment of the study group (n = 7) altered the hemodynamic response, thus maximal systemic vasodilation and stroke volume increase at a lower diltiazem dose, a 15 to 35% increase in myocardial work and power, and more profound coronary vasodilation."( Positive hemodynamic interaction between amrinone and diltiazem in anesthetized dogs.
Chartrand, C; Dagher, E; Dumont, L, 1989
)
1.26
"The amrinone-treated dogs had lower PaO2 and higher venous admixture than the control dogs.(ABSTRACT TRUNCATED AT 250 WORDS)"( Amrinone administration in endotoxin shock.
Cantraine, F; Contempré, B; de Boelpaepe, C; Domb, M; Motte, S; Van der Linden, P; Vincent, JL, 1988
)
2.2
"Treatment with amrinone potentiated the relaxant responses of mesenteric arteries to adenosine but did not alter the response to isoprenaline."( Responses of isolated dog arteries to amrinone.
Miyazaki, M; Nakajima, M; Nishimura, K; Toda, N, 1984
)
0.88
"Pretreatment with amrinone significantly decreased endothelial E-selectin surface values at all concentrations (p < .001 by analysis of variance, n = 5), including therapeutic concentration ranges."( Inotropes inhibit endothelial cell surface adhesion molecules induced by interleukin-1beta.
Fortenberry, JD; Huber, AR; Owens, ML, 1997
)
0.62
"Pretreatment with amrinone, and to a lesser degree, with dopamine, at clinically relevant concentrations inhibits in vitro IL-1alpha-induced increases in human umbilical vein endothelial cell adhesion molecule concentrations. "( Inotropes inhibit endothelial cell surface adhesion molecules induced by interleukin-1beta.
Fortenberry, JD; Huber, AR; Owens, ML, 1997
)
0.63
"Treatment with amrinone or placebo was initiated upon release of the aortic cross-clamp, before weaning from cardiopulmonary bypass."( Prophylactic amrinone for weaning from cardiopulmonary bypass.
Appadurai, IR; Bode, RH; Halpern, EF; Lewis, KP; Pierce, ET, 2000
)
1.02
"Pretreatment with amrinone was able to diminish a decrease in Pao(2) during endotoxemia, indicating that pulmonary dysfunction was attenuated. "( Influence of amrinone on tissue oxygenation of jejunal mucosa during endotoxemia.
Gebhard, MM; Martin, E; Schmidt, H; Schmidt, W; Tinelli, M; Walther, A, 2000
)
1.01

Toxicity

ExcerptReferenceRelevance
" No adverse effects were recorded in any of the patients."( Evaluation of the safety and efficacy of amrinone in chronic obstructive lung disease with cor pulmonale.
Arens, M; De Waele, R; Demedts, M; Meirhaeghe, J; Van den Brande, P; Van Mieghem, W, 1990
)
0.54
"The results of the subchronic toxicity studies gave in mini-LEWE-pigs no toxic effects for the substance Cordemcura."( [Subchronic toxicity testing of Cordemcura in the mini-Lewe minipig].
Göres, E; Janowski, K; Landmann, H, 1986
)
0.27
" Adverse reactions were complicated by underlying disease severity and concomitant drug therapy."( Clinical safety of intravenous amrinone--a review.
Treadway, G, 1985
)
0.56
" The most significant adverse effects were cardiac arrhythmias, thrombocytopenia, abnormal results of liver function tests, diarrhea, fever, and nausea."( Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure.
Gerber, L; Merrill, AJ; Silverman, BD, 1985
)
0.54
" Other potentially serious adverse effects were: abdominal pain (two patients), nausea and vomiting (three patients), jaundice (one patient), myositis (one patient), pulmonary infiltrates (two patients), and polyserositis (one patient)."( Side effects of amrinone therapy.
Webb-Peploe, MM; Wilsmhurst, PT, 1983
)
0.61
" All of these animals also survived with no apparent adverse effects."( Reversal of propranolol blockade of adrenergic receptors and related toxicity with drugs that increase cyclic AMP.
Alleva, FR; Balazs, T; Joseph, X; Vick, JA; Whitehurst, VE; Zhang, J, 1999
)
0.3
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

Amrinone was administered orally as a single 100-mg dose to six male patients with moderate-severe congestive heart failure. The mean (SD) apparent oral clearance, apparent volume of distribution at steady state and half-life of amrinone were 0.

ExcerptReferenceRelevance
"The pharmacokinetic characteristics of amrinone have been studied in six female marmosets following oral administration of 1, 12."( The relationship between the pharmacokinetics of amrinone in the marmoset and platelet effects.
Bonner, FW; Eason, CT; Henry, GP; Powles, P; Usansky, JI,
)
0.65
" After either oral or parenteral administration of milrinone, plasma levels were dose dependent and the drug had an apparent first-order terminal elimination half-life of approximately 2 hr."( Pharmacokinetics of the bipyridines amrinone and milrinone.
Benotti, J; Benziger, DP; Chatterjee, K; Cody, R; Edelson, J; Hood, WB; Krebs, C; Luczkowec, C; Schwartz, R; Stroshane, R, 1986
)
0.55
"Amrinone was administered orally as a single 100-mg dose to six male patients with moderate-severe congestive heart failure to determine the acute pharmacodynamic effects and pharmacokinetics of the drug."( Acute pharmacodynamics and pharmacokinetics of oral amrinone.
Benotti, JR; Lesko, LJ; McCue, JE, 1982
)
1.96
" There was a large variability in the volume of distribution, clearance, and elimination half-life which did not appear to be age-related."( Age-related amrinone pharmacokinetics in a pediatric population.
Allen-Webb, EM; Banner, W; McGough, EC; Pappas, JB; Ross, MP, 1994
)
0.67
"This case report details the pharmacokinetic adjustments of an amrinone infusion in a paediatric patient who developed multiorgan system failure with anuric renal failure and was prescribed continuous arteriovenous haemofiltration."( Effect of continuous arteriovenous haemofiltration on pharmacokinetics of amrinone.
Azin, S; Corddry, D; Lawless, S; Restaino, I, 1993
)
0.76
" These drugs must be administered parenterally and have a half-life of only a few minutes."( Clinical pharmacokinetics of vasodilators. Part II.
Heintz, B; Kirsten, D; Kirsten, R; Nelson, K, 1998
)
0.3
" The elimination half-life of amrinone was 10."( Pharmacokinetics of amrinone in neonates and infants.
Ahonen, J; Laitinen, P; Olkkola, KT; Peltola, K; Räsänen, J; Rautiainen, P, 2000
)
0.92
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Compound-Compound Interactions

Amorphone is rapidly effective during weaning from CPB and, in combination with norepinephrine, provides the necessary inotropic support during this unstable period.

ExcerptReferenceRelevance
") in combination with dobutamine and dopamine."( [Successful use of amrinone in combination with dobutamine in the treatment of severe heart failure].
Firt, P; Málek, I; Vojtísková, J, 1989
)
0.61
"Effects of amrinone (AMR), a phosphodiesterase inhibitor, alone and in combination with dobutamine (DOB), on hemodynamics and O2 delivery were studied during porcine endotoxemia."( Amrinone combined with dobutamine improves hemodynamics and oxygen delivery without down-regulation of cardiac beta-adrenergic receptor density in porcine endotoxemia.
Dodam, JR; Gengo, PJ; Hellyer, PW; Jones, JL, 1995
)
2.12
" Amrinone is rapidly effective during weaning from CPB and, in combination with norepinephrine, provides the necessary inotropic support during this unstable period."( Amrinone, in combination with norepinephrine, is an effective first-line drug for difficult separation from cardiopulmonary bypass.
Hardy, JF; Perrault, J; Roy, M; Searle, N, 1993
)
2.64
"min-1) (NTG group, n = 5), combined with dopamine (3-5 mg."( [Hemodynamic effects of amrinone combined with dopamine in patients undergoing living renal transplantation].
Hagihira, S; Inagaki, Y; Mashimo, T; Mori, T; Okuno, Y; Takashina, M; Yoshiya, I, 1997
)
0.6

Bioavailability

ExcerptReferenceRelevance
" Milrinone is well absorbed orally and has a duration of action of three to six hours."( Milrinone, a new agent for the treatment of congestive heart failure.
Hasegawa, GR, 1986
)
0.27
" These data suggest that verapamil, and partially amrinone, inhibit histamine-induced tracheal contractions by reducing the bioavailability of intracellular Ca2+."( Relaxant effects of amrinone upon pulmonary smooth muscle.
Buck, DC; Mielens, ZE, 1982
)
0.84
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Amrinone relaxed the strips precontracted by KCl, norepinephrine, serotonin or STA2 in a dose-dependent manner. Current dosage recommendations are inadequate in neonates and infants.

ExcerptRelevanceReference
" Insufficient dosage may explain the lack of haemodynamic effect, while possible reasons for the higher SvO2 and lower VO2 are either reduced whole body VO2 or peripheral shunting."( Amrinone before termination of cardiopulmonary bypass: haemodynamic variables and oxygen utilization in the postbypass period.
Bilodeau, J; DeJesus, JM; O'Connor, JP; Ralley, FE; Ramsay, JG; Robbins, GR; Wynands, JE, 1992
)
1.73
" As an initial step toward elucidating the optimal dosage of amrinone for cardiac surgical patients we studied the pharmacokinetics of amrinone during and after cardiac surgery requiring cardiopulmonary bypass."( Pharmacokinetics of amrinone during cardiac surgery.
Bailey, JM; Hug, CC; Levy, JH; Rogers, HG; Szlam, F, 1991
)
0.85
" Adverse effects are minimal, with dosage limited predominantly by decreases in filling pressures."( Intravenous use of amrinone for the treatment of the failing heart.
LeJemtel, T; Mancini, D; Sonnenblick, E, 1985
)
0.6
"The haemodynamic dose-response effects of intravenous amrinone were measured in 16 male patients, aged 40-65 years, with radiographic and haemodynamic evidence of left ventricular failure 4-18 h after acute myocardial infarction."( Haemodynamic dose-response effects of intravenous amrinone in left ventricular failure complicating acute myocardial infarction.
Hafizullah, M; Jackson, NC; Reynolds, GW; Silke, B; Taylor, SH; Verma, SP,
)
0.63
" The following were the most significant effects of MDL 19205: a decrease in action potential duration in both ventricular and Purkinje tissues; a cumulative dose-dependent increase in contractile force in ventricular muscle but not in Purkinje strands; no change in aiNa in Purkinje fibers to accompany the positive inotropic effect of this agent; a shift in the dose-response relation by approximately fourfold in the presence of beta-adrenergic blockade with sotalol (10(-7) M); an enhancement of diastolic depolarization in Purkinje fibers resulting in automaticity that is accelerated by overdrive; and a potentiation of the positive inotropic effects of MDL 19205 by 8-bromo-cAMP (1 mM), indicating a potent phosphodiesterase inhibitory action of MDL 19205."( Effects of MDL 19205 (piroximone), a new cardiotonic agent, on electrophysiological, mechanical, and intracellular ionic characteristics of sheep cardiac tissues.
Wasserstrom, JA,
)
0.13
" Amrinone relaxed the strips precontracted by KCl, norepinephrine, serotonin or STA2 in a dose-dependent manner, and it shifted the dose-response curves downward."( Involvement of cyclic AMP in vasodilatation by amrinone: a comparative study with 3-isobutyl-methyl-xanthine (IBMX).
Kishi, Y; Numano, F, 1986
)
1.44
"The comparative haemodynamic dose-response effects of intravenous (i."( Comparative haemodynamic dose-response effects of dobutamine and amrinone in left ventricular failure complicating acute myocardial infarction.
Midtbo, KA; Reynolds, G; Silke, B; Taylor, SH; Verma, SP, 1987
)
0.51
"On isolated electrically stimulated left and spontaneously beating right guinea-pig atria the interaction between PDE-inhibitors and the positive inotropic and chronotropic action of orciprenaline, forskolin and histamine in dose-response curve was examined."( Interaction of phosphodiesterase inhibitors triamterene, papaverine, theophylline, IBMX and amrinone with other positive inotropic acting substances on isolated guinea-pig atria.
Greeff, K; Schmitt, M, 1987
)
0.49
" To achieve the plasma concentration of amrinone that is therapeutic in adults, current dosage recommendations are inadequate in neonates and infants."( Amrinone in neonates and infants after cardiac surgery.
Burckart, G; Diven, W; Lawless, S; Siewers, R; Thompson, A, 1989
)
1.99
" It can be concluded from these results that, in situ, the primary action of amrinone occurs on vascular smooth muscle and that a positive inotropic activity with a normal dosage of amrinone is only an indirect outcome of reflex activation of the sympathetic system."( Haemodynamic effects of amrinone in the anaesthetized pig.
Brilla, C; Jacob, R; Kissling, G; Vogt, M, 1988
)
0.81
" Catecholamine dosage was held constant during the period of the study."( Effect of amrinone in acute severe cardiac failure.
Frenking, B; Gülker, H; Heuer, H, 1988
)
0.68
" In the high dosage group stomach and intestinal bleedings were seen macroscopically, but no histological changes were found."( [Chronic toxicity testing of Cordemcura].
Janowski, K; Stade, K; Zschorn, EM, 1986
)
0.27
" The dose-response curve of left ventricular dP/dt and performance during titration of dobutamine with and without the addition of intravenous amrinone was evaluated in seven patients."( Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure.
Gage, J; LeJemtel, TH; Lucido, D; Rutman, H, 1986
)
0.75
"5 mg/kg tid and increasing to a maximum dosage of 200 mg tid."( Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial.
Bourassa, M; DiBianco, R; Hess, M; Konstam, M; Likoff, M; Massie, B; Packer, M, 1985
)
0.55
"Hemodynamic dose-response effects of intravenous amrinone were studied in 22 male patients aged 38 to 62 years with left ventricular failure occurring within 18 hours of acute myocardial infarction."( Intravenous amrinone in left ventricular failure complicated by acute myocardial infarction.
Hafizullah, M; Hussain, M; Jackson, NC; Reynolds, G; Richmond, A; Silke, B; Taylor, SH; Verma, SP, 1985
)
0.9
" Holter recordings (24 to 48 hours) were obtained from 10 patients before and after acute oral amrinone dosing (75 to 150 mg every 8 hours)."( Amrinone: acute electrophysiologic and hemodynamic effects in patients with congestive heart failure.
Dougherty, AH; Goldstein, RA; Gray, EL; Hanna, JE; Naccarelli, GV, 1984
)
1.93
" Dose-response curves for sodium nitroprusside, nitroglycerin, isoproterenol, amrinone, and PGE1 were then generated."( Pulmonary vascular smooth muscle relaxation by cGMP- versus cAMP-mediated mechanisms.
Banerjee, A; Fullerton, DA; Hahn, AR; Harken, AH, 1994
)
0.52
"To measure the plasma concentrations of amrinone and N-acetyl-amrinone achieved using current pediatric dosing recommendations."( Age-related amrinone pharmacokinetics in a pediatric population.
Allen-Webb, EM; Banner, W; McGough, EC; Pappas, JB; Ross, MP, 1994
)
0.94
" Blood concentrations of amrinone determined (only in the amrinone group) after separation from CPB confirmed that the dosage of amrinone produced an effective blood concentration."( Amrinone in cardiac surgical patients with left-ventricular dysfunction. A prospective, randomized placebo-controlled trial.
Butterworth, JF; Lawless, ST; Prielipp, RC; Royster, RL; Wallenhaupt, SL, 1993
)
2.03
" A brief review of this institution's preference for amrinone follows, including its pharmacology, side effects, and dosing prior to separation from CPB."( Early intervention of inotropic support in facilitating weaning from cardiopulmonary bypass: the New England Deaconess Hospital experience.
Lewis, KP, 1993
)
0.54
" Among them, 3,4-dipropyl-4,5,7,8-tetrahydro-3H-imidazo[1,2-i]-purin-5-one (1c), which was the most selective and potent PDE IV inhibitor, did not cause emesis in Suncus murinus at a dosage range of 10-100 mg/kg (po), while an imidazole analogue of 1c (4c) and known PDE IV inhibitors such as rolipram and denbufylline caused emesis even at 10 or 30 mg/kg."( Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
Kasugai, S; Miyamoto, K; Ohya, K; Sawanishi, H; Suzuki, H; Suzuki, N; Takagi, K; Waki, Y; Yamamoto, S, 1997
)
0.3
"With this dosage regimen, amrinone provides a higher cardiac output, more favorable oxygen dynamics, and lower pulmonary vascular resistance than dopamine and nitroglycerin."( Amrinone versus dopamine-nitroglycerin after reconstructive surgery for complete atrioventricular septal defect.
Happonen, JM; Korpela, R; Laitinen, P; Leijala, M; Peltola, K; Rautiainen, P; Sairanen, H, 1997
)
2.04
" After preconstriction with the selective alpha1-adrenergic-receptor agonist phenylephrine dose-response curves were constructed for amrinone (1-270 microg x min(-1)), enoximone (1-270 microg x min(-1)), theophylline (5-1500 microg x min(-1)) and pentoxifylline (2-877 microg x min(-1)) in a random order on separate occasions."( Dilatory effects of phosphodiesterase inhibitors on human hand veins in vivo.
Braune, J; Ebert, U; Grossmann, M; Kirch, W, 1998
)
0.5
" Amrinone, milrinone and olprinone dose-dependently increased left ventricular max dp/dt, and the estimated slope of the dose-response curve for olprinone was significantly sharper than that of amrinone."( [Effects of amrinone on renal blood flow and cardiac function, in comparison with those of milrinone and olprinone, in anesthetized dog].
Fujishima, K; Hachisu, M; Yamamoto, A, 1998
)
1.59
"With the dosage regimen used, supplemented with epinephrine, amrinone provides a higher cardiac output and more favorable oxygen dynamics than a combination of dopamine and nitroglycerin."( Amrinone versus dopamine and nitroglycerin in neonates after arterial switch operation for transposition of the great arteries.
Happonen, JM; Laitinen, P; Peltola, K; Rautiainen, P; Sairanen, H, 1999
)
1.99
" We found a shift in the dose-response curve of only phosphodiesterase 5 inhibitors."( The effect of chronic renal failure on phosphodiesterase inhibitor-induced relaxation responses in rabbit cavernosal strips.
Bagcivan, I; Gokce, G; Kilicarslan, H; Sarac, B; Sarioglu, Y; Yildirim, S, 2003
)
0.32
" Our aim was to compare the dose-response electrophysiologic, mechanical, vasodilatory, and metabolic properties of three clinically available phosphodiesterase inhibitors in isolated Langendorff perfused guinea pig hearts."( A comparison of three phosphodiesterase type III inhibitors on mechanical and metabolic function in guinea pig isolated hearts.
Graf, BM; Grube, C; Martin, E; Stowe, DF; Zausig, YA; Zink, W, 2006
)
0.33
" Health-system pharmacists should be aware that when these drugs are used as antidotes, higher than normal dosing is needed."( Treatment of poisoning caused by beta-adrenergic and calcium-channel blockers.
Shepherd, G, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
EC 3.1.4.* (phosphoric diester hydrolase) inhibitorAn EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a phosphoric diester hydrolase (EC 3.1.4.*).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
bipyridinesCompounds containing a bipyridine group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (104)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency18.25630.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency44.66840.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency3.09510.140911.194039.8107AID2451
Chain A, HADH2 proteinHomo sapiens (human)Potency5.62950.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency5.62950.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency18.92720.177814.390939.8107AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency27.82980.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency0.28185.623417.292931.6228AID485281
thioredoxin reductaseRattus norvegicus (Norway rat)Potency64.77570.100020.879379.4328AID588453; AID588456
15-lipoxygenase, partialHomo sapiens (human)Potency12.13290.012610.691788.5700AID2157; AID887
phosphopantetheinyl transferaseBacillus subtilisPotency49.61360.141337.9142100.0000AID1490; AID2701; AID2707
RAR-related orphan receptor gammaMus musculus (house mouse)Potency25.75740.006038.004119,952.5996AID1159521; AID1159523
ATAD5 protein, partialHomo sapiens (human)Potency7.30780.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency54.80570.031637.5844354.8130AID504865; AID743255
GLS proteinHomo sapiens (human)Potency31.62280.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency24.84860.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency5.05590.180013.557439.8107AID1460; AID1468; AID1558; AID1559
AR proteinHomo sapiens (human)Potency26.60320.000221.22318,912.5098AID743042
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency16.87470.011212.4002100.0000AID1030
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency3.98110.00137.762544.6684AID914; AID915
hypothetical protein, conservedTrypanosoma bruceiPotency50.11870.223911.245135.4813AID624173
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency42.56030.001022.650876.6163AID1224838; AID1224893
regulator of G-protein signaling 4Homo sapiens (human)Potency44.66840.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.54870.01237.983543.2770AID1645841
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.53570.000229.305416,493.5996AID743069
GVesicular stomatitis virusPotency10.96400.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency12.30180.00108.379861.1304AID1645840
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency29.84700.001024.504861.6448AID743212
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.01550.023723.228263.5986AID743223
alpha-galactosidaseHomo sapiens (human)Potency1.25894.466818.391635.4813AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency25.14590.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency9.68850.000723.06741,258.9301AID743122
thyroid stimulating hormone receptorHomo sapiens (human)Potency21.13170.001628.015177.1139AID1259385
Histone H2A.xCricetulus griseus (Chinese hamster)Potency113.00400.039147.5451146.8240AID1224845
Bloom syndrome protein isoform 1Homo sapiens (human)Potency22.38720.540617.639296.1227AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency12.58930.00207.533739.8107AID891
polyunsaturated fatty acid lipoxygenase ALOX12Homo sapiens (human)Potency17.78281.000012.232631.6228AID1452
cytochrome P450 2C19 precursorHomo sapiens (human)Potency5.01190.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency12.58930.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency13.35730.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency19.95260.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency17.95370.010039.53711,122.0200AID1469; AID1567; AID1570; AID1573; AID588547
huntingtin isoform 2Homo sapiens (human)Potency0.50120.000618.41981,122.0200AID1688
importin subunit beta-1 isoform 1Homo sapiens (human)Potency60.29815.804836.130665.1308AID540253; AID540263
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency29.93490.168316.404067.0158AID720504
snurportin-1Homo sapiens (human)Potency60.29815.804836.130665.1308AID540253; AID540263
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency14.54100.000627.21521,122.0200AID743202; AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency22.38720.425612.059128.1838AID504891
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency20.59625.804816.996225.9290AID540253
DNA polymerase eta isoform 1Homo sapiens (human)Potency89.12510.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency10.00000.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency31.62280.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency0.05170.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency11.55750.031610.279239.8107AID884; AID885
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency14.12540.00419.962528.1838AID2675
caspase-1 isoform alpha precursorHomo sapiens (human)Potency29.88160.000311.448431.6228AID900
lamin isoform A-delta10Homo sapiens (human)Potency0.31620.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency100.00006.309660.2008112.2020AID720709
Interferon betaHomo sapiens (human)Potency10.96400.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency12.58930.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency11.55751.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency10.96400.01238.964839.8107AID1645842
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency23.93410.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
MPI proteinHomo sapiens (human)IC50 (µMol)50.00000.190013.825650.1000AID1220
perilipin-5Homo sapiens (human)IC50 (µMol)78.81600.98503.45659.4680AID504319
perilipin-1Homo sapiens (human)IC50 (µMol)79.47600.92503.30339.6190AID504317
1-acylglycerol-3-phosphate O-acyltransferase ABHD5 isoform aHomo sapiens (human)IC50 (µMol)79.14600.92503.58289.6190AID504317; AID504319
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)IC50 (µMol)656.00000.00001.77679.2000AID157004; AID157005; AID157009; AID158289
Aurora kinase AHomo sapiens (human)Ki393.90000.00000.20021.4000AID1410656
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)212.93330.11007.190310.0000AID1443980; AID1449628; AID1473738
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)IC50 (µMol)113.60000.00001.068010.0000AID159508; AID159509; AID159515; AID160138
Dual specificity protein kinase TTKHomo sapiens (human)Ki80.80000.15000.15000.1500AID1410655
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)IC50 (µMol)1,000.00000.23002.510510.0000AID156989; AID156990; AID156991; AID156992; AID158886
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)IC50 (µMol)1,000.00000.00002.14179.2000AID156989; AID156990; AID156991; AID156992; AID158886
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)IC50 (µMol)113.60000.00001.104010.0000AID159508; AID159509; AID159515; AID160138
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)IC50 (µMol)113.60000.00001.465110.0000AID159508; AID159509; AID159515; AID160138
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)IC50 (µMol)113.60000.00001.146310.0000AID159508; AID159509; AID159515; AID160138
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)IC50 (µMol)52.87500.00002.072410.0000AID157142; AID157144; AID157145; AID158301; AID158303; AID159340; AID159377; AID220013
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)IC50 (µMol)1,000.00000.23001.98149.0000AID156989; AID156990; AID156991; AID156992; AID158886
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)IC50 (µMol)52.87500.00031.990110.0000AID157142; AID157144; AID157145; AID158301; AID158303; AID159340; AID159377; AID220013
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
Aurora kinase BHomo sapiens (human)Ki59.30000.00000.02610.3500AID1410657
Inner centromere proteinHomo sapiens (human)Ki59.30000.00000.00060.0015AID1410657
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (242)

Processvia Protein(s)Taxonomy
heart valve developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
ventricular septum developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
aorta developmentcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP catabolic processcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of inflammatory responsecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
establishment of endothelial barriercGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to mechanical stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cAMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to cGMPcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxinecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
positive regulation of gene expressioncGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cGMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
regulation of mitochondrion organizationcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
signal transductioncAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
sensory perception of smellcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of protein kinase A signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle organizationDual specificity protein kinase TTKHomo sapiens (human)
positive regulation of cell population proliferationDual specificity protein kinase TTKHomo sapiens (human)
female meiosis chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to meiotic spindle midzoneDual specificity protein kinase TTKHomo sapiens (human)
chromosome segregationDual specificity protein kinase TTKHomo sapiens (human)
peptidyl-serine phosphorylationDual specificity protein kinase TTKHomo sapiens (human)
protein localization to kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
mitotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
meiotic spindle assembly checkpoint signalingDual specificity protein kinase TTKHomo sapiens (human)
regulation of smooth muscle cell apoptotic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cGMP catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
regulation of smooth muscle cell proliferationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
response to amphetamineCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
locomotory behaviorCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
visual learningCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
monocyte differentiationCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
dopamine catabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
serotonin metabolic processCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cellular response to granulocyte macrophage colony-stimulating factor stimulusCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
neutrophil homeostasiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
neutrophil chemotaxiscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
leukocyte migrationcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to lipopolysaccharidecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to xenobiotic stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cellular response to epinephrine stimuluscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of adenylate cyclase-activating adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP catabolic processcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of heart ratecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulumcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of type II interferon productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-2 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
positive regulation of interleukin-5 productioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of peptidyl-serine phosphorylationcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of heart contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
T cell receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
establishment of endothelial barriercAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
adrenergic receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cardiac muscle cell contractioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of cell communication by electrical coupling involved in cardiac conductioncAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
negative regulation of relaxation of cardiac musclecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP-mediated signalingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesioncGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of angiogenesiscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cellular response to insulin stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of cell adhesion mediated by integrincGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of lipid catabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cAMP-mediated signalingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
oocyte maturationcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
lipid metabolic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
response to xenobiotic stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of meiotic nuclear divisioncGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of apoptotic processcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of vascular permeabilitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
steroid hormone mediated signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of cAMP-mediated signalingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
positive regulation of oocyte developmentcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
regulation of ribonuclease activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to cGMPcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cellular response to transforming growth factor beta stimuluscGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
apoptotic signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwaycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIAurora kinase BHomo sapiens (human)
mitotic cell cycleAurora kinase BHomo sapiens (human)
mitotic cytokinesisAurora kinase BHomo sapiens (human)
negative regulation of B cell apoptotic processAurora kinase BHomo sapiens (human)
protein phosphorylationAurora kinase BHomo sapiens (human)
spindle organizationAurora kinase BHomo sapiens (human)
attachment of spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
abscissionAurora kinase BHomo sapiens (human)
negative regulation of protein bindingAurora kinase BHomo sapiens (human)
positive regulation of telomere maintenance via telomeraseAurora kinase BHomo sapiens (human)
negative regulation of cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of cytokinesisAurora kinase BHomo sapiens (human)
protein localization to kinetochoreAurora kinase BHomo sapiens (human)
cellular response to UVAurora kinase BHomo sapiens (human)
cleavage furrow formationAurora kinase BHomo sapiens (human)
post-translational protein modificationAurora kinase BHomo sapiens (human)
cell cycle G2/M phase transitionAurora kinase BHomo sapiens (human)
mitotic cytokinesis checkpoint signalingAurora kinase BHomo sapiens (human)
negative regulation of innate immune responseAurora kinase BHomo sapiens (human)
protein autophosphorylationAurora kinase BHomo sapiens (human)
mitotic spindle midzone assemblyAurora kinase BHomo sapiens (human)
positive regulation of telomerase activityAurora kinase BHomo sapiens (human)
regulation of chromosome segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid segregationAurora kinase BHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointAurora kinase BHomo sapiens (human)
mitotic spindle assemblyAurora kinase BHomo sapiens (human)
negative regulation of cGAS/STING signaling pathwayAurora kinase BHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase BHomo sapiens (human)
positive regulation of mitotic sister chromatid separationAurora kinase BHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
positive regulation of mitotic cytokinesisAurora kinase BHomo sapiens (human)
positive regulation of telomere cappingAurora kinase BHomo sapiens (human)
positive regulation of lateral attachment of mitotic spindle microtubules to kinetochoreAurora kinase BHomo sapiens (human)
mitotic spindle organizationAurora kinase BHomo sapiens (human)
regulation of cytokinesisAurora kinase BHomo sapiens (human)
mitotic cell cycleInner centromere proteinHomo sapiens (human)
mitotic cytokinesisInner centromere proteinHomo sapiens (human)
chromosome segregationInner centromere proteinHomo sapiens (human)
mitotic spindle midzone assemblyInner centromere proteinHomo sapiens (human)
positive regulation of mitotic cell cycle spindle assembly checkpointInner centromere proteinHomo sapiens (human)
mitotic spindle assemblyInner centromere proteinHomo sapiens (human)
positive regulation of mitotic sister chromatid separationInner centromere proteinHomo sapiens (human)
positive regulation of attachment of mitotic spindle microtubules to kinetochoreInner centromere proteinHomo sapiens (human)
positive regulation of mitotic cytokinesisInner centromere proteinHomo sapiens (human)
metaphase chromosome alignmentInner centromere proteinHomo sapiens (human)
meiotic spindle midzone assemblyInner centromere proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (83)

Processvia Protein(s)Taxonomy
magnesium ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP-stimulated cyclic-nucleotide phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
zinc ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cAMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cGMP bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
TPR domain bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
phosphate ion bindingcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein homodimerization activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
protein tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein bindingDual specificity protein kinase TTKHomo sapiens (human)
ATP bindingDual specificity protein kinase TTKHomo sapiens (human)
identical protein bindingDual specificity protein kinase TTKHomo sapiens (human)
kinetochore bindingDual specificity protein kinase TTKHomo sapiens (human)
protein serine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
protein serine/threonine kinase activityDual specificity protein kinase TTKHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
protein bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
enzyme bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
signaling receptor regulator activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cAMP bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
beta-2 adrenergic receptor bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
transmembrane transporter bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
metal ion bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
ATPase bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
scaffold protein bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
heterocyclic compound bindingcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
protein kinase B bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated dual specificity 3',5'-cyclic-GMP, 3',5'-cyclic-AMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
metal ion bindingCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
calmodulin-activated 3',5'-cyclic-GMP phosphodiesterase activityCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
3',5'-cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-AMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cGMP-inhibited cyclic-nucleotide phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
protein bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
nuclear estrogen receptor activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
metal ion bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
3',5'-cyclic-GMP phosphodiesterase activitycGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
estrogen bindingcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase BHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase BHomo sapiens (human)
protein bindingAurora kinase BHomo sapiens (human)
ATP bindingAurora kinase BHomo sapiens (human)
kinase bindingAurora kinase BHomo sapiens (human)
protein serine kinase activityAurora kinase BHomo sapiens (human)
protein bindingInner centromere proteinHomo sapiens (human)
molecular function activator activityInner centromere proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (85)

Processvia Protein(s)Taxonomy
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
endoplasmic reticulumcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
Golgi apparatuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
plasma membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
presynaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
nucleuscGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial inner membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
perinuclear region of cytoplasmcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial outer membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
synaptic membranecGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
cytosolcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
mitochondrial matrixcGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
ruffle membranecAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)
cytoplasmDual specificity protein kinase TTKHomo sapiens (human)
spindleDual specificity protein kinase TTKHomo sapiens (human)
membraneDual specificity protein kinase TTKHomo sapiens (human)
kinetochoreDual specificity protein kinase TTKHomo sapiens (human)
nucleusDual specificity protein kinase TTKHomo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1BHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
synaptic vesiclecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
postsynaptic densitycAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
Z disccAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
dendritic spinecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
excitatory synapsecAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
gamma-tubulin complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)
extracellular spacecAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
ciliumcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)
centrosomecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
apical plasma membranecAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
voltage-gated calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
calcium channel complexcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
cytosolcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
nucleuscAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
perinuclear region of cytoplasmcAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)
endoplasmic reticulumcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
Golgi apparatuscGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
guanyl-nucleotide exchange factor complexcGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)
lysosomeCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
neuronal cell bodyCalcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1CHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
membranecGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
cytosolcGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
condensed chromosome, centromeric regionAurora kinase BHomo sapiens (human)
nucleusAurora kinase BHomo sapiens (human)
nucleoplasmAurora kinase BHomo sapiens (human)
spindleAurora kinase BHomo sapiens (human)
cytosolAurora kinase BHomo sapiens (human)
chromocenterAurora kinase BHomo sapiens (human)
microtubule cytoskeletonAurora kinase BHomo sapiens (human)
midbodyAurora kinase BHomo sapiens (human)
chromosome passenger complexAurora kinase BHomo sapiens (human)
mitotic spindle poleAurora kinase BHomo sapiens (human)
mitotic spindle midzoneAurora kinase BHomo sapiens (human)
kinetochoreAurora kinase BHomo sapiens (human)
spindle pole centrosomeAurora kinase BHomo sapiens (human)
spindle microtubuleAurora kinase BHomo sapiens (human)
spindle midzoneAurora kinase BHomo sapiens (human)
chromosome, centromeric regionInner centromere proteinHomo sapiens (human)
kinetochoreInner centromere proteinHomo sapiens (human)
lateral elementInner centromere proteinHomo sapiens (human)
central elementInner centromere proteinHomo sapiens (human)
nucleoplasmInner centromere proteinHomo sapiens (human)
spindleInner centromere proteinHomo sapiens (human)
cytosolInner centromere proteinHomo sapiens (human)
microtubuleInner centromere proteinHomo sapiens (human)
chromocenterInner centromere proteinHomo sapiens (human)
microtubule cytoskeletonInner centromere proteinHomo sapiens (human)
nuclear bodyInner centromere proteinHomo sapiens (human)
midbodyInner centromere proteinHomo sapiens (human)
chromosome passenger complexInner centromere proteinHomo sapiens (human)
pericentric heterochromatinInner centromere proteinHomo sapiens (human)
protein-containing complexInner centromere proteinHomo sapiens (human)
kinetochoreInner centromere proteinHomo sapiens (human)
nucleusInner centromere proteinHomo sapiens (human)
meiotic spindle midzoneInner centromere proteinHomo sapiens (human)
midbodyInner centromere proteinHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (320)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID77425Inotropic effect in electrically driven left atrium from reserpine-treated guinea pig at the concentration of 5 x 10 e-4 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID89399In vitro inhibition of collagen stimulated platelet aggregation in human whole blood1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID77146Effect on contractile force of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 10 e-3 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID222887Effect on the frequency rate of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 10E-5 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID62402Positive inotropic activity in anesthetized dogs1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.
AID1221971Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221961Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1410663Inhibition of RSK1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID159509Inhibition of canine kidney Phosphodiesterase 4 at 0.5 uM1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and cardiotonic activity of novel biimidazoles.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID44921Activity against [Ca2+]-ATPase assay in rabbit myocardial membrane.1995Journal of medicinal chemistry, May-26, Volume: 38, Issue:11
Structure-activity relationships of milrinone analogues determined in vitro in a rabbit heart membrane Ca(2+)-ATPase model.
AID5965350% increase in myocardial contractile force (CF) above control in anesthetized open-chest dogs at 1.875 mg/kg intravenous dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
AID158910Inhibitory activity against PDE1 from cerebral cortex1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
AID61106Effect on arterial blood pressure (MAP) in anesthetized open-chest dogs at 1.875 mg/kg intravenous dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID59872Percent increase in contractility was evaluated by effect of Cardiotonic agents on myocardial contractility in conscious dog administered orally at dose of 10 mg/kg1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID60152Inotropic activity determined by evaluating the % change in Cardiac out put (CO)at a dose of 100 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID1410684Inhibition of ABL (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID157009Inhibitory concentration against cAMP PDE II enzyme in guinea pig1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl
AID156991Inhibitory concentration against cAMP PDE I enzyme in guinea pig1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID77149Effect on contractile force of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 10 e-4 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID1155746Vasorelaxant activity in Wistar rat endothelium-intact thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis, biological evaluation and structure-activity relationships of new phthalazinedione derivatives with vasorelaxant activity.
AID1410659Inhibition of MPS1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID59457Hemodynamic activity in anesthetized dog as percent change from baseline (2271 mmHg/s) in left ventricular myocardial activity at 1 mg/kg administered intravenously1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID77271Effect on frequency rate of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 10 e-3 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID156989Inhibition of cAMP PDE I enzyme1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
AID159523Inhibition of canine heart Phosphodiesterase 4 at 100 uM1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.
AID1410674Inhibition of INSR (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID59298Positive inotropic activity determined in the isolated papillary muscle of the dog(that produced 30% increase in dose- response curves [dP/dt(max)])1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID220013Cardiotonic effect by inhibition of cAMP phosphodiesterase (PDE III)1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.
AID59873Percent increase in contractility was evaluated by effect of Cardiotonic agents on myocardial contractility in conscious dog administered orally at dose of 3.1 mg/kg1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID1410672Inhibition of LYN (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID49582Compound was evaluated for positive inotropic activity in vitro on cat papillary muscle, expressed as the percent increase over base-line contractility at 1 x 10 e-4 M1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Ligand-receptor interactions via hydrogen-bond formation. Synthesis and pharmacological evaluation of pyrrolo and pyrido analogues of the cardiotonic agent 7-hydroxycyclindole.
AID1410681Inhibition of CHK1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID80774Inhibition of ADP-induced platelet aggregation in guinea pig whole blood at 5*10e-4 M1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID92394In vitro inhibition of collagen stimulated platelet aggregation in human thrombocyte enriched plasma1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID77277Effect on frequency rate of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 10 e-5 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID50434Compound tested for contractility in isolated cat papillary muscle at 10 e-4 M.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID156990Inhibition cGMP PDE I enzyme1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
AID157142Inhibition of canine cardiac fraction III cAMP phosphodiesterase (PDE 3) at 1.875 mg/kg intravenous dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
AID157004Inhibition of cAMP PDE II enzyme1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
AID220008Compound was evaluated for its inotropic activity by the inhibition of cAMP Phosphodiesterase enzyme1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID76176Effect on contractile force of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 2 x 10 e-3 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1410683Inhibition of AKT1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID59879Percent increase in heart rate was evaluated by effect of Cardiotonic agents on myocardial contractility in conscious dog administered orally at dose of 3.1 mg/kg1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID222885Effect on the frequency rate of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 10E-3 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID1221964Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1410664Inhibition of PRAK (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID222884Effect on the contractile force of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 3 x 10E-6 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID60654Decreased mean arterial blood pressure in anesthetized dogs after intravenous administration (no data)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-ones.
AID220542Percent change in heart rate in anesthetized dog1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID229699Ratio of IC50 values for PDE III and PDE I.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl
AID222881Effect on the contractile force of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 10E-6 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID222758Effect on the contractile force of spontaneously beating atria from Reserpine treated guinea pigs as percentage variation from the control at concentration of 10E-4 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID158301Inhibition of low Km cyclic cAMP phosphodiesterase PDE III of guinea pig ventricle1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID1410667Inhibition of PKA (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID159340Inhibition of Phosphodiesterase 3 from human platelets at 1E-7-1E-4M or 1.0E-6 to 1E-3 M1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID49060Response ratio = (percent increase to drug)/(percent increase to 10 E-5 M isoproterenol)1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1221962Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1221979Transporter substrate index ratio of permeability from basolateral to apical side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1410677Inhibition of ERK2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID60148Inotropic activity determined by evaluating the % change in contractile force (CF) of right ventricle at a dose of 300 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID106807Compound was tested for the inhibition of malate dehydrogenase (MDH) at 50 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1221960Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID60281Inotropic activity determined by evaluating the % change in Heart Rate (HR) at a dose of 1000 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60145Inotropic activity determined by evaluating the % change in contractile force (CF) of right ventricle at a dose of 100 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1410668Inhibition of P38alpha (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID158303Inhibition of fraction III of guinea pig phosphodiesterase1984Journal of medicinal chemistry, Sep, Volume: 27, Issue:9
Cardiotonic agents. 1. 4,5-Dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3 (2H)-pyridazinones: novel positive inotropic agents for the treatment of congestive heart failure.
AID60290Inotropic activity determined by evaluating the % change in Systolic Blood Pressure (SBP) at a dose of 100 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID59501Cardiotonic activity in increasing contractility in phenobarbital-anesthetized dogs after intravenous administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.
AID1410676Inhibition of FYN (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID1410662Inhibition of SRC (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID77426Inotropic effect in electrically driven left atrium from reserpine-treated guinea pig at the concentration of 5 x 10 e-5 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID92392In vitro inhibition of ADP stimulated platelet aggregation in human thrombocyte enriched plasma1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID210767Tested in vitro for tracheal relaxation1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID222757Effect on the contractile force of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 10E-3 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID1410680Inhibition of CHK2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1410679Inhibition of CK1delta (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID1410666Inhibition of PKCzeta (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID61607Inotropic activity determined by evaluating the maximum rate of rise in left ventricular pressure at a dose of 300 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID157005Inhibition of cGMP PDE II enzyme1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
AID157145Inhibitory concentration against cAMP PDE III enzyme in guinea pig1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl
AID77268Effect on contractile force of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 5x 10 e-5 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID231474Relative inhibition of cardiac and platelet PDE31989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID58972Cardiotonic activity by increasing heart rate (HR) in phenobarbital-anesthetized dogs after intravenous administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.
AID1221957Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID59893Increased heart rate in anesthetized dogs after intravenous administration (no data)1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-ones.
AID222882Effect on the contractile force of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 3 x 10E-4 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID222880Effect on the contractile force of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 10E-5 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID28953Logarithm of the sum of contributions of each atom to the total lipophilicity of the molecule1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1221973Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1221958Efflux ratio of permeability from apical to basolateral side over basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID1410665Inhibition of PKD2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID61114Effect on myocardial contractile force (CF) in anesthetized open-chest dogs at 1.875 mg/kg intravenous dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
AID59024Cardiotonic activity by decreasing mean arterial blood pressure(MAP) in phenobarbital-anesthetized dogs after intravenous administration1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Bipyridine cardiotonics: the three-dimensional structures of amrinone and milrinone.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID50436Compound tested for contractility in isolated cat papillary muscle at 10 e-5 M.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID1221978Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID80783Inhibition of arachidonic acid induced platelet aggregation in guinea pig whole blood at 5*10e-4 M1991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1410671Inhibition of MAPKAPK2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID60151Inotropic activity determined by evaluating the % change in Cardiac out put (CO)at a dose of 1000 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID40531Positive inotropic effects by direct or indirect beta-1 adrenergic receptor activation.1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
In search of the digitalis replacement.
AID77421Inotropic effect in electrically driven left atrium from reserpine-treated guinea pig at the concentration of 10 e-3 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID159508Inhibition of canine heart Phosphodiesterase 41990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and cardiotonic activity of novel biimidazoles.
AID61603Inotropic activity determined by evaluating the maximum rate of rise in left ventricular pressure at a dose of 1000 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1221956Apparent permeability from apical to basolateral side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID59456Hemodynamic activity in anesthetized dog as percent change from baseline (2271 mmHg/s) in left ventricular myocardial activity at 0.3 mg/kg administered intravenously1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID1221980Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID59878Percent increase in heart rate was evaluated by effect of Cardiotonic agents on myocardial contractility in conscious dog administered orally at dose of 10 mg/kg1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1410673Inhibition of LCK (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID1410678Inhibition of ERK1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID160138Inhibitory activity against Phosphodiesterase 4 from heart.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
AID230124Ratio of positive inotropic activity to peripheral Vasodilator activity in dogs1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1410669Inhibition of MSK1 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1410661Inhibition of Aurora B (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID52790Inhibition of chymotrypsin at 250 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID158886Inhibition of [Ca(2+)]/calmodulin dependent phosphodiesterase PDE 1 of guinea pig ventricle1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1410657Inhibition of human full length N-terminal GST-tagged Aurora B (1 to 344 end residues)/His-tagged INCENP (803 to 918 end residues) expressed in baculovirus expression system using fluorescence-labeled FL-Peptide 21 as substrate after 60 mins in presence o2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID89398In vitro inhibition of ADP stimulated platelet aggregation in human whole blood1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID77152Effect on contractile force of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 10 e-5 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID60158Inotropic activity determined by evaluating the % change in Diastolic Blood Pressure (DBP) at a dose of 1000 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID60289Inotropic activity determined by evaluating the % change in Systolic Blood Pressure (SBP) at a dose of 1000 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID159515Inhibition of canine heart phosphodiesterase 41991Journal of medicinal chemistry, Oct, Volume: 34, Issue:10
New 5H-pyridazino[4,5-b]indole derivatives. Synthesis and studies as inhibitors of blood platelet aggregation and inotropics.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID61110Effect on heart rate (HR) in anesthetized open-chest dogs at 1.875 mg/kg intravenous dose1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis and cardiotonic activity of a series of substituted 4-alkyl-2(1H)-quinazolinones.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID77423Inotropic effect in electrically driven left atrium from reserpine-treated guinea pig at the concentration of 10 e-5 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID1410670Inhibition of MET (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID591741Inhibition of Itk at 30 uM after 40 mins by radiometric phosphate incorporation assay2011Journal of medicinal chemistry, Apr-14, Volume: 54, Issue:7
Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID60282Inotropic activity determined by evaluating the % change in Heart Rate (HR) at a dose of 100 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID59617Peak percent change in contractile force produced after iv administration at 0.3 mg/kg in ansthetetized dog1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and cardiotonic activity of novel biimidazoles.
AID159513Inhibition of canine kidney Phosphodiesterase 41990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and cardiotonic activity of novel biimidazoles.
AID60170Myocardial contractility in anesthetized dogs on intravenous administration1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-ones.
AID1155747Vasorelaxant activity in Wistar rat endothelium-denuded thoracic aortic rings assessed as inhibition of phenylephrine-induced contraction2014European journal of medicinal chemistry, Jul-23, Volume: 82Synthesis, biological evaluation and structure-activity relationships of new phthalazinedione derivatives with vasorelaxant activity.
AID60162Inotropic activity determined by evaluating the % change in Diastolic Blood Pressure (DBP) at a dose of 300 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID61604Inotropic activity determined by evaluating the maximum rate of rise in left ventricular pressure at a dose of 100 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1221972Apparent permeability from basolateral to apical side of human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 10 uM of MRP2 inhibitor MK5712011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID77284Effect on frequency rate of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 5 x 10 e-4 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1410675Inhibition of GSK3beta (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID222890Compound was evaluated for its effect on the frequency rate of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 3 x 10E-4 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID159377Inhibitory activity against Phosphodiesterase 3 from heart.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
AID5930750% increase in myocardial contractility (dP/dt max) in anesthetized dogs on intravenous dose1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID158570Inhibition of phosphodiesterase 3 from guinea pig cardiac tissue at 1E-7-1E-4M or 1.0E-6 to 1E-3 M1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID76178Effect on frequency rate of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 2 x 10 e-3 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID60293Inotropic activity determined by evaluating the % change in Systolic Blood Pressure (SBP) at a dose of 300 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID1221963Transporter substrate index ratio of permeability from apical to basolateral side in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID229700Ratio of IC50 values for PDE III and PDE II.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1410682Inhibition of AKT2 (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID222883Effect on the contractile force of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 3 x 10E-5 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID80440Compound was tested in vitro for positive chronotropic action.1997Journal of medicinal chemistry, Sep-26, Volume: 40, Issue:20
Selective inhibitors of cyclic AMP-specific phosphodiesterase: heterocycle-condensed purines.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID219840Inhibition of Sarcoplasmic Reticulum cAMP Phosphodiesterase from canine myocardium1987Journal of medicinal chemistry, May, Volume: 30, Issue:5
Dihydropyridazinone cardiotonics: synthesis and inotropic activity of 5'-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)spiro[cycloalkane- 1,3'-[3H]indol]-2'(1'H)-ones.
AID60159Inotropic activity determined by evaluating the % change in Diastolic Blood Pressure (DBP) at a dose of 100 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID222886Effect on the frequency rate of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 10E-4 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID77158Effect on contractile force of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 5x 10 e-4 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID58608Evaluated for 50% increase of myocardial contractility in anesthetized dog, administered intravenously1985Journal of medicinal chemistry, Oct, Volume: 28, Issue:10
Cardiotonic agents. 2. Synthesis and structure-activity relationships of 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones: a new class of positive inotropic agents.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID60285Inotropic activity determined by evaluating the % change in Heart Rate (HR) at a dose of 300 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID222888Effect on the frequency rate of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 10E-6 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID159199In vitro inhibitory activity against cAMP phosphodiesterase III in dog aorta1994Journal of medicinal chemistry, Jan-21, Volume: 37, Issue:2
Novel cAMP PDE III inhibitors: imidazo[4,5-b]pyridin-2(3H)-ones and thiazolo[4,5-b]pyridin-2(3H)-ones and their analogs.
AID1221965Transporter substrate index of efflux ratio in human Caco2 cells at 10 uM up to 120 mins by HPLC-MC analysis in presence of 1 uM of P-gp inhibitor LY3359792011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID59485Compound tested for contractility in anesthetized dog when administered intravenously.1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID59455Hemodynamic activity in anesthetized dog as percent change from baseline (2271 mmHg/s) in left ventricular myocardial activity at 0.1 mg/kg administered intravenously1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID1410660Inhibition of Aurora A (unknown origin) at 100 uM using peptide as substrate in presence of ATP and MgCl2 by mobility shift assay relative to control2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID60155Inotropic activity determined by evaluating the % change in Cardiac out put (CO)at a dose of 300 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID1221982Fraction absorbed in human2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
AID157144Inhibition of cAMP PDE III enzyme1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 8. Selective inhibitors of adenosine 3',5'-cyclic phosphate phosphodiesterase III. Elaboration of a five-point model for positive inotropic activity.
AID222892Compound was evaluated for its effect on the frequency rate of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 3 x 10E-6 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID1443980Inhibition of human BSEP expressed in fall armyworm sf9 cell plasma membrane vesicles assessed as reduction in vesicle-associated [3H]-taurocholate transport preincubated for 10 mins prior to ATP addition measured after 15 mins in presence of [3H]-tauroch2010Toxicological sciences : an official journal of the Society of Toxicology, Dec, Volume: 118, Issue:2
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
AID59458Hemodynamic activity in anesthetized dog as percent change from baseline (2271 mmHg/s) in left ventricular myocardial activity at 3.1 mg/kg administered intravenously1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID222891Compound was evaluated for its effect on the frequency rate of spontaneously beating atria from Reserpine-treated guinea pigs as percentage variation from the control at concentration of 3 x 10E-5 M1996Journal of medicinal chemistry, Sep-13, Volume: 39, Issue:19
Synthesis and cardiotonic activity of novel pyrimidine derivatives: crystallographic and quantum chemical studies.
AID158289Inhibition of cyclic GMP sensitive phosphodiesterase PDE 2 of guinea pig ventricle1985Journal of medicinal chemistry, May, Volume: 28, Issue:5
A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID77424Inotropic effect in electrically driven left atrium from reserpine-treated guinea pig at the concentration of 2 x 10 e-3 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID59675Effective dose required to increase myocardial contractility in dog.1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl
AID1410656Inhibition of full length N-terminal His-tagged Aurora A (unknown origin) using fluorescence-labeled FL-Peptide 21 as substrate after 60 mins in presence of ATP by fluorescence assay based Cheng-Prusoff equation analysis2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID60144Inotropic activity determined by evaluating the % change in contractile force (CF) of right ventricle at a dose of 1000 ug/kg administered intravenously in isolated papillary muscle of the dog1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID220543Percent change in mean arterial blood pressure in anesthetized dog1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID77274Effect on frequency rate of spontaneously beating atria from reserpine treated guinea pigs at the concentration of 10 e-4 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID59137Positive inotropic in the isolated papillary muscle of the dog.1987Journal of medicinal chemistry, Jul, Volume: 30, Issue:7
A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino)phenyl]pyridazinones and related derivatives.
AID1410655Inhibition of full length human Mps1 using fluorescence-labeled H236 peptide as substrate after 60 to 90 mins in presence of ATP by fluorescence assay based Cheng-Prusoff equation analysis2018Bioorganic & medicinal chemistry, 07-15, Volume: 26, Issue:11
Synthesis and profiling of a 3-aminopyridin-2-one-based kinase targeted fragment library: Identification of 3-amino-5-(pyridin-4-yl)pyridin-2(1H)-one scaffold for monopolar spindle 1 (MPS1) and Aurora kinases inhibition.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID77422Inotropic effect in electrically driven left atrium from reserpine-treated guinea pig at the concentration of 10 e-4 M1993Journal of medicinal chemistry, Aug-20, Volume: 36, Issue:17
A pharmacological, crystallographic, and quantum chemical study of new inotropic agents.
AID156992Inhibitory concentration against cGMP PDE I enzyme in guinea pig1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Cardiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correl
AID49059Response ratio = (percent increase to drug)/(percent increase to 10 E-4 M isoproterenol)1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Structure-activity relationships of arylimidazopyridine cardiotonics: discovery and inotropic activity of 2-[2-methoxy-4-(methylsulfinyl)phenyl]-1H-imidazo[4,5-c]pyridine.
AID1345205Human phosphodiesterase 3A (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))1989Journal of medicinal chemistry, Feb, Volume: 32, Issue:2
Cardiotonic agents. 9. Synthesis and biological evaluation of a series of (E)-4,5-dihydro-6-[2-[4-(1H-imidazol-1-yl)phenyl]ethenyl]-3 (2H)-pyridazinones: a novel class of compounds with positive inotropic, antithrombotic, and vasodilatory activities for t
AID1345238Human phosphodiesterase 3B (Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs))2000Biochemical pharmacology, Feb-15, Volume: 59, Issue:4
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (779)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990372 (47.75)18.7374
1990's289 (37.10)18.2507
2000's79 (10.14)29.6817
2010's31 (3.98)24.3611
2020's8 (1.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 50.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index50.94 (24.57)
Research Supply Index6.82 (2.92)
Research Growth Index4.18 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (50.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials78 (9.35%)5.53%
Reviews81 (9.71%)6.00%
Case Studies48 (5.76%)4.05%
Observational0 (0.00%)0.25%
Other627 (75.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]